SG11201906169QA - Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid - Google Patents
Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acidInfo
- Publication number
- SG11201906169QA SG11201906169QA SG11201906169QA SG11201906169QA SG11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- ursodeoxycholic acid
- composition
- visual impairments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170018220 | 2017-02-09 | ||
| KR1020180015944A KR102252450B1 (ko) | 2017-02-09 | 2018-02-08 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
| PCT/KR2018/001770 WO2018147685A1 (ko) | 2017-02-09 | 2018-02-09 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906169QA true SG11201906169QA (en) | 2019-08-27 |
Family
ID=63443030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906169QA SG11201906169QA (en) | 2017-02-09 | 2018-02-09 | Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190255074A1 (ko) |
| EP (1) | EP3581185A4 (ko) |
| JP (2) | JP6901739B2 (ko) |
| KR (3) | KR102252450B1 (ko) |
| CN (1) | CN110177556A (ko) |
| AU (3) | AU2018218696B2 (ko) |
| BR (1) | BR112019009202A2 (ko) |
| CA (1) | CA3039500C (ko) |
| GB (1) | GB2571644A (ko) |
| MX (1) | MX2019008963A (ko) |
| RU (2) | RU2723988C1 (ko) |
| SG (1) | SG11201906169QA (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| KR102252450B1 (ko) * | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
| EP3900728A4 (en) | 2018-12-18 | 2022-08-17 | Santen Pharmaceutical Co., Ltd. | AGENT CONTAINING URSODESOXYCHOLIC ACID FOR TREATING OR PREVENTING PRESBYOPIA |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| KR102624174B1 (ko) | 2020-09-18 | 2024-01-23 | 주식회사 아미코젠파마 | 수가용화된 담즙산을 포함하는 패혈증, 급성 폐손상 질환, 또는 급성 호흡곤란증후군의 예방 또는 치료용 약학 조성물 |
| KR20230145458A (ko) | 2021-02-15 | 2023-10-17 | 산텐 세이야꾸 가부시키가이샤 | 우르소데옥시콜산 또는 그 염을 함유하는 수성 의약 조성물 |
| CN113151206A (zh) * | 2021-04-21 | 2021-07-23 | 重庆第二师范学院 | 一种3α-羟基类固醇脱氢酶、编码基因及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4790123B2 (ja) * | 1998-07-24 | 2011-10-12 | ヨー、セオ、ホン | 胆汁酸を有する透明水溶液型製剤の調剤 |
| US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| EP1255566A2 (en) * | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| BRPI0514725A (pt) * | 2004-08-30 | 2008-06-24 | Seo Hong Yoo | efeito neuroprotetor de udca solubilizado no modelo isquêmico focal |
| DE602005025391D1 (de) * | 2004-11-01 | 2011-01-27 | Seo Hong Yoo | Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose |
| ES2358089T3 (es) * | 2004-11-01 | 2011-05-05 | Seo Hong Yoo | Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica. |
| BRPI0419213A (pt) * | 2004-11-24 | 2007-12-18 | Seo Hong Yoo | formas secas de formulação de dosagem de ácido biliar solubilizada aquosa: preparação e usos destas |
| KR20080012258A (ko) * | 2005-02-10 | 2008-02-11 | 리전츠 오브 더 유니버스티 오브 미네소타 | 시각장애를 치료하는 방법 |
| KR20080061327A (ko) * | 2006-12-27 | 2008-07-02 | 성균관대학교산학협력단 | 가용성 ｕｄｃａ를 포함하는 직장암 예방 및 치료 조성물 |
| WO2010123156A1 (ja) * | 2009-04-23 | 2010-10-28 | 国立大学法人鹿児島大学 | 血管新生抑制剤 |
| US9724357B2 (en) * | 2011-08-15 | 2017-08-08 | Massachusetts Eye & Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
| TW201609145A (zh) * | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | 注射劑及形成緩釋（ｄｅｐｏｔ）之方法 |
| WO2015112831A1 (en) | 2014-01-23 | 2015-07-30 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
| CN104083381A (zh) * | 2014-07-29 | 2014-10-08 | 上海中医药大学 | 熊去氧胆酸的医药用途 |
| KR102252450B1 (ko) * | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
-
2018
- 2018-02-08 KR KR1020180015944A patent/KR102252450B1/ko active IP Right Grant
- 2018-02-09 JP JP2019520858A patent/JP6901739B2/ja active Active
- 2018-02-09 EP EP18751361.9A patent/EP3581185A4/en not_active Withdrawn
- 2018-02-09 CN CN201880005395.0A patent/CN110177556A/zh active Pending
- 2018-02-09 SG SG11201906169QA patent/SG11201906169QA/en unknown
- 2018-02-09 MX MX2019008963A patent/MX2019008963A/es unknown
- 2018-02-09 GB GB1904993.1A patent/GB2571644A/en not_active Withdrawn
- 2018-02-09 RU RU2019111077A patent/RU2723988C1/ru active
- 2018-02-09 CA CA3039500A patent/CA3039500C/en active Active
- 2018-02-09 BR BR112019009202-1A patent/BR112019009202A2/pt not_active Application Discontinuation
- 2018-02-09 RU RU2020115283A patent/RU2746592C1/ru active
- 2018-02-09 AU AU2018218696A patent/AU2018218696B2/en active Active
-
2019
- 2019-05-01 US US16/400,969 patent/US20190255074A1/en not_active Abandoned
- 2019-11-25 KR KR1020190152527A patent/KR102382077B1/ko active IP Right Grant
-
2020
- 2020-06-30 AU AU2020204384A patent/AU2020204384B2/en active Active
-
2021
- 2021-04-07 US US17/224,731 patent/US20210252022A1/en not_active Abandoned
- 2021-06-10 JP JP2021096995A patent/JP2021143192A/ja active Pending
- 2021-07-02 AU AU2021204660A patent/AU2021204660A1/en not_active Abandoned
- 2021-12-24 KR KR1020210187626A patent/KR20220000881A/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20190255074A1 (en) | 2019-08-22 |
| CA3039500C (en) | 2021-07-13 |
| KR102382077B1 (ko) | 2022-04-04 |
| GB201904993D0 (en) | 2019-05-22 |
| CA3039500A1 (en) | 2018-06-16 |
| KR20220000881A (ko) | 2022-01-04 |
| AU2020204384B2 (en) | 2021-10-21 |
| GB2571644A (en) | 2019-09-04 |
| KR20190135955A (ko) | 2019-12-09 |
| EP3581185A4 (en) | 2020-10-28 |
| CN110177556A (zh) | 2019-08-27 |
| MX2019008963A (es) | 2019-09-10 |
| KR20180092886A (ko) | 2018-08-20 |
| JP2019532082A (ja) | 2019-11-07 |
| AU2020204384A1 (en) | 2020-07-23 |
| KR102252450B1 (ko) | 2021-05-14 |
| JP6901739B2 (ja) | 2021-07-14 |
| EP3581185A1 (en) | 2019-12-18 |
| JP2021143192A (ja) | 2021-09-24 |
| RU2723988C1 (ru) | 2020-06-18 |
| RU2746592C1 (ru) | 2021-04-16 |
| AU2018218696B2 (en) | 2020-04-09 |
| AU2018218696A1 (en) | 2019-06-13 |
| AU2021204660A1 (en) | 2021-07-29 |
| BR112019009202A2 (pt) | 2020-03-03 |
| US20210252022A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906169QA (en) | Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid | |
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| MX2023003124A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
| MX350951B (es) | Composiciones y metodos para tratar enfermedades retinales. | |
| WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| MX2015012435A (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| PH12017502155A1 (en) | Formation of cyclosporin a/cyclodextrin nanoparticles | |
| MX2023003230A (es) | Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida. | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| BR112022011102A2 (pt) | Tratamentos do edema macular diabético e da acuidade visual deficiente | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| WO2015187840A3 (en) | Methods and formulations for treatment of ocular disorders | |
| WO2013189606A3 (en) | Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases | |
| MX2017004760A (es) | Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. | |
| EP4245295A3 (en) | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| MX2021006070A (es) | Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. | |
| AU2018240462A1 (en) | Drugs and compositions for the treatment of ocular disorders | |
| MX2021012960A (es) | Composiciones y metodos de uso de cannabinoides para neuroproteccion. | |
| MX2017016858A (es) | Composiciones inmunogenicas. | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. |